Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
Iain J AbbottJohan W MoutonAnton Y PelegJoseph MeletiadisPublished in: The Journal of antimicrobial chemotherapy (2021)
With the exception of E. coli, fosfomycin is a poor target for other uropathogen species. A reduction in oral fosfomycin UTI breakpoints is supported.